FIELD: pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to producing interferon-containing suppositories. Interferon-containing suppository comprises a fatty base, emulsifier and human lyophilized interferon purified from low-molecular and high-molecular components of the definite antiviral activity. Mixture of mono-, di- and triglycerides and saturated fatty acids from coconut oil and palm oil of sort "Vitepsol" H-15 and W-35 taken in equal ratio are used as a fatty base. Distilled monoglycerides taken in the definite ratio are used as an emulsifier. Above describes suppositories retain specific activity and effectiveness in treatment of viral and bacterial diseases for a long time and show stability against mechanical effects.
EFFECT: improved and valuable properties of suppository.
1 tbl, 1 ex
The invention relates to the manufacture of candles with interferon and can be used in the medical industry to obtain drugs for the treatment and prevention of viral and bacterial infections.
The closest technical solution of the present composition are suppositories containing interferon, the body's framework and emulsifier (RF Patent No. 2201212, CL AC 9/02, publ. 27.03. 2003).
The disadvantage of this drug is unstable forms to mechanical stress during packaging and transportation, the rapid decline in activity, low physical and biological properties, short term storage.
The present invention is to obtain suppositories with interferon with property preservation of physical and biological properties during long-term storage, as well as increased stability of the dosage forms to mechanical stress during packaging and transportation.
The technical result, which can be obtained by carrying out the invention, is in the long-term preservation specific activity and efficacy in the treatment of viral and bacterial diseases.
For this purpose, the suppositories as interferon is used lyophilized human leukocyte interferon purified from low molecular weight and a professional who cularly components with antiviral activity not less than 25000 ME/ as a fat basis use a mixture of tri-, di - and monoglycerides and saturated fatty acids from coconut and palm oils brand "Witepsol" H-15 and W-35 in equal proportions, and as an emulsifier used distilled monoglycerides in the ratio of 0.5% by weight of the candles.
The method of producing suppositories with interferon includes the following stages:
Obtaining a purified substance interferon, in particular natural, is as follows: prefabricated interferon (IFN) is tested for sterility, the presence of a regulated level of antiviral activity, the absence of infectious virus inductor, toxicity and non-specific impurities, as well as the lack of surface antigen of the hepatitis C virus (HCV), antibodies to HIV types 1 and 2. Prefabricated natural interferon clear one of the regulated methods using gelfiltration using Sephadex brand G-25 (coarse) (V.P. Kuznetsov "the Modern conception of the use and manufacture of medical preparations of interferon". Sat. "The interferon system in health and disease". Edited FI Ershov, Medicine, 1996, PP 156-171), or by ultrafiltration through the membrane polysulfone plate with a nominal cut-off 100-300 KD with subsequent clipping of low molecular weight compounds 10-20 KD.
Sterile prefabricated interferon activity not less than 25,000 IU/, bottled in sterilized the basic metallic cartridge. A cassette cover with a sterile drug of a napkin and then a metal cover. The process of freeze drying comprises freeze of the drug at low temperature and sublimation. Cassette with spilled product put on the freeze in low temperature counter NS-700/ 50 or ILICA-2000. In one of the cassettes with spilled product installed on the top shelf of the stack put the Pt-100 sensor for hourly temperature recording freezing of the drug. The freezing temperature not higher than minus 40°C for at least 16 hours with forced ventilation and not less than 24 hours without forced ventilation. The final freezing temperature of not higher than minus 45°C.
The drying is conducted at industrial installations for lyophilization TG 50.4 regime drying of the drug Interferon human leukocyte dry". When the condenser temperature not higher than minus 50°and the temperature of the shelves is not higher than 20°With metal cover to remove cassettes, tapes with frozen drug quickly loaded into the freeze-installing apparatus for freeze-drying, the camera is closed and vacuum pumps. At the end of the process, the vacuum in sublimator "extinguish" nitrogen through sterilizing filters up to full pressure equalization. The camera open, the cartridge tightly closed metal lids./p>
Collection of lyophilized IFN carried out in the zone of laminar air flow. Using a sterile metal spatula preparation of the cassette is transferred into a sterile container, which is closed by a stopper, seal with paraffin or balconywith. Store to use in the next stage of the technological process in the refrigerator at a temperature of plus (6±2)°C.
Dried powder of IFN before making a suppository is controlled by the following parameters: antiviral activity of interferon, solubility, pH, sterility.
To provide the necessary structural-mechanical properties and uniform distribution of IFN in suppozitornyj based emulsifiers are used distilled monoglycerides (MHD) in the ratio of 0.5% by weight of the candles. The melting point of suppositories thus does not increase, and its structural and mechanical properties streamline the packing of suppositories with IFN.
In addition, the data for the study of experimentally produced series of suppositories prepared on the basis of witepsol two kinds - N-15 and W-35 in different variants showed that the best structural-mechanical properties are suppositories that witepsol N-15 and W-35 taken in 1:1 ratio.
The capacity to melt the basics of load-weighted number monagle is erodov distilled, at the same time into the second tank fat basis and melted for 20 minutes at a temperature of plus (60±1)°With the bath water laboratory with electric heating. Heat-resistant vessel with a fat basis and MHD cover with foil, paper and sterilized in an autoclave at a pressure of 0.5 kgf/cm2temperatures above 110°C for 30 minutes. Sterile witepsol and MHD melted in a water bath at a temperature of (38±2)°and mix them into one of the tanks. Then load the powder interferon and mix until smooth. The temperature of the process must be within plus (38±2)°that is achieved by temperature control of the container for preparing suppozitornoj mass. Suppozitornyj the masses poured into the socket of the metal molds. The mold is cooled at a temperature of minus 12±2)°C.
1100 suppository average weight of 1.35 g weight suppozitornoj mass taking into account losses (0.2% - when filtering witepsol and distilled monoglycerides, 9.8 percent - when filling suppozitornoj mass in the mold of 2.7% when filling in the contour packaging without cells) will be 1,673 kg
Powder interferon - 18 l (0,072 kg).
Weight basis 1,673-0,072=1,601 kg
Of distilled monoglycerides - 0.5% of suppozitornoj mass, i.e. 0,0083 kg
Comparative evaluation of physical properties and specifications the practical activity of suppositories with IFN, prepared on various lipophilic bases, are presented in the table.
The data presented show that the optimum is the seventh option to obtain suppositories with a long shelf-life, specific activity, and also provides sufficient strength, crack resistance and shape retention of the drug in the packaging, transportation and storage.
|Comparison of quality indicators suppositories with IFN prepared with different lipophilic bases, during storage|
|Options used suppozitornyj bases with IFN||Shelf life Lek. shape, mo.||Indicators|
|Melting point, °C||The full deformation, min||The activity of IFN, IU/St.||Appearance|
|1. Solid confectionery fat T-2||0||40||7,0||40000|
|When packaging laminated paper partially melted|
|2. Solid confectionery fat Paraffin, is -2||0||52||8,0||40000|
|When packaging laminated paper partially melted|
|H. Witepsol N -15||0||37||7,5||40000|
|Partly on the suppositories are formed cracks|
|4. Witepsol N-15 + Witepsol W-35 (2:1)||0||37||6,0||40000|
|Very fragile, broken|
|5. Witepsol W-35||0||37,5||7,0||40000|
|Partly on the suppositories are formed cracks|
|6. Witepsol-15+ Witepsol W-35 (1:1)||0||37,5||8,0||40000|
|Partly on the suppositories are formed cracks|
|7. Witepsol N-15 + Witepsol W-35 (1:1)+MHD||0||38||8,0||40000|
|Cracks, breakage and fusion during the packaging is not marked|
Suppositories with interferon containing fat-based and emulsifier, characterized in that the composition is administered lyophilized human leukocyte interferon, purified from low molecular weight and high molecular weight components with antiviral activity not less than 25,000 IU/g, as a fat basis use a mixture of tri-, di - and monoglycerides and saturated fatty acids from coconut and palm oils brand "Witepsol" H-15 and W-35 in equal proportions, and as an emulsifier use distilled monoglycerides, and interferon take in the amount of 4.3%, fat basis is 65.5%and monoglycerides - 0.5% of the weight suppozitornoj mass.
SUBSTANCE: method involves forming group of 6 or more years old children leaving Far North regions. Rudivax vaccine is administered to these children not later than 60 days before departure. Another children group, arriving to Far North regions from other climate regions, is vaccinated not earlier than in 70 days after their arrival.
EFFECT: enhanced effectiveness of vaccination.
SUBSTANCE: claimed method includes application of chimera flavivirus, including capsid and non-structural proteins of yellow fever virus, prM protein, and envelope protein of West Nile encephalitis virus as drug for prophylaxis of infection caused by West Nile virus in horses.
EFFECT: prophylaxis of infection caused by West Nile virus in horses.
FIELD: medicine, virology.
SUBSTANCE: invention relates to therapeutic using of hepatitis virus C purified envelope protein E1. Invention involves using purified recombinant truncated protein E1 HCV 192-326 for preparing a prophylactic composition that in the effective dose is able to induce protection from conversion of acute hepatitis to its chronic form in mammal infected with hepatitis virus C. Protein E1 HCV 192-326 represents a single or oligomeric protein that is not bound with other contaminating proteins by disulfide bond. Advantage of the invention involves detection of prophylactic effectiveness in conversion of acute form to chronic one in protein E1 HCV 192-326 in infection with hepatitis virus C.
EFFECT: valuable medicinal properties of viral protein.
61 cl, 13 tbl, 18 ex
FIELD: peptides, medicine, immunology.
SUBSTANCE: invention relates to novel methods for producing family of antigenic peptides possessing antiviral effect, and to peptide libraries obtained by using indicated methods, and to compositions based on thereof. Method for producing antigenic peptides involves detection of a great number of variable positions in protein site of pathogenic organism; selection of peptide sequence in protein of pathogenic organism comprising a great number of variable positions; selection of one or more substituting amino acid residues for one of variable positions or sequences possessing antigenic affinity with amino acid residues in variable position of this protein in natural conditions by using a matrix of antigenic similarity of amino acids showing possibility for substitution of one amino acid residue with another residue and with retaining interaction of antibody with antigen and corrected in correspondence with amino acids frequencies in hypervariable sites; incorporation of selected substituting amino acid residues into peptide sequence; synthesis of family of antigenic peptides. Also, invention relates to a method for calling the immune response and to a method for diagnosis of HIV-infection by using family of peptides prepared according to methods of the invention.
EFFECT: valuable biological and medicinal properties of peptides, improved preparing method.
233 cl, 43 tbl, 1 dwg, 5 ex
FIELD: organic chemistry, pharmacy, veterinary science.
SUBSTANCE: invention relates to compound comprising 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridine-4-amine or pharmaceutically acceptable salt of this compound and pharmaceutical composition used for stimulation of biosynthesis of cytokine based on abovementioned compound Also, invention claims a method for stimulation of biosynthesis of cytokines in animal body involving administration in animal body of above described compound or its salt. Invention provides preparing a novel compound possessing useful biological properties.
EFFECT: valuable biological properties of compound and pharmaceutical composition.
3 cl, 12 tbl, 213 ex
FIELD: medicine, in particular new PAGylated interferon against viral infection.
SUBSTANCE: invention relates to PAGylated interferon of formula CH3OCH2CH2(OCH2CH2)2-O-SO2CH2-protein, wherein protein represents interferon, and average molecular mass of polyethylene glycol units is 13000-17000 Da. Also disclosed are pharmaceutical composition containing PAGylated interferon of present invention and pharmaceutically acceptable carrier, and method for controlling of vital infection by administering of PAGylated interferon of present invention in effective amount.
EFFECT: new PAGylated interferon against viral infection.
6 cl, 1 tbl, 6 ex, 1 dwg
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to novel analogues of 2',5'-oligoadenylate represented by the general formula (1): or their pharmacologically acceptable salts possessing antiviral and antitumor activity, to a pharmaceutical composition based on thereof, and their using as a medicinal agent in preparing a medicinal agent. In the formula (1) E1 represents group of the formula (K2): ; E2 represents group of the formula (K1): ; E3 represents group of the formula (K2) or (K3): , and E4 represents group of the formula (K1), (K2), (K3) or (K4): . Values of substitutes R1 - R8, m, n, A, B and D are given in the invention claim.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
10 cl, 4 tbl, 1 graph, 90 ex
FIELD: homeopathy, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to creature of homeopathic agents possessing antiviral effect. Invention proposes two variants of agent. Homeopathic agent possessing antiviral effect comprises the following components: black elder (Sambucus nigra), speedwell officinalis (Veronica), shrubby dewberry (Rubus fructicosus), yellow jasmine (Gelsemium sempervirens), ferric (III) phosphate (Ferrum phosphoricum), common toadflax (Linaria), common whiteweed (Chrysanthemum leucanthemum), leaf-perforated thoroughwort (Eupatorium perfoliatum), planted everlasting pea (Lathyrus sativus) and pallid coneflower (Echinacea pallida) taken in the equal ratio and in dilution of each component 1D-30C. Agent possessing antiviral and antibacterial effect comprises monkshood (Aconitum napellus), deadly nightshade (Atropa belladonna), tinctorial baptisia (Baptisia tictoria), yellow jasmine (Gelsemium sempervirens), ferric (III) phosphate (Ferrum phosphoricum) white bryony (Bryonia falba), onion (Allium cepa), mercurius solubilis by Hahneman (Mercurius solubilis Hahnemani), perforated thoroughwort (Eupatorium perfoliatum), pallid coneflower Echinacea pallida) taken in the equal ratio and in dilution of each component 1D-30C. Proposed agents can be prepared as drops, granules and capsules. Agent provides the active effect on viruses and accelerates recovery processes in body. Invention can be used in treatment of patients with influenza, avian influenza, in prophylaxis and treatment of poultries damaged with virus H5N1 and in other acute respiratory-viral infections of different localization.
EFFECT: enhanced effectiveness and valuable medicinal properties of agent.
FIELD: organic chemistry, pharmaceuticals.
SUBSTANCE: invention relates to arylether-substituted imidazoquinolines and tetrahydroimidazoquinolines useful in inducing of cytokines biosynthesis. In particular described are imidazoquinolines of formula I wherein X represents -CHR3; R1 represents aryl, R4-aryl; R2 represents hydrogen atom, alkyl, aryl, tetrahydrofuran; alkyl-Y-alkyl; alkyl-Y-aryl, and alkyl substituted with one or more substituents; R are independently C1-C10-alkyl, C1-C10- alkoxy, hydroxyl group; halogen atom, and trifluoromethyl or pharmaceutically acceptable salts thereof; meanings of the rest substituents are as defined in description. Also disclosed are pharmaceutical compositions for inducing of cytokines biosynthesis, methods for treatment of viral and tumor diseases.
EFFECT: new compounds with value biological properties.
39 cl, 8 tbl, 146 ex
FIELD: medicine, in particular immunogenic composition.
SUBSTANCE: claimed composition contains antigens of A and B influenza viruses, sorbed on Bifidobacterium bifidum bacterial cultures, immobilized on acceptable sorbent.
EFFECT: increased immunogenicity.
2 cl, 2 ex, 5 tbl, 2 dwg
FIELD: chemical-and pharmaceutical industry.
SUBSTANCE: claimed agent contains DNA sodium salt isolated from bovine testis and is useful in peroral application in form of powder, tablets, pellets, and capsules for treatment and prophylaxis of anemia, secondary immunodeficit conditions and as bracing agent. Agent may additionally contains biologically active components and filler.
EFFECT: effective and convenient agent having antianemic, immunomodulating and adaptogenic actions.
3 cl, 3 ex, 6 tbl
FIELD: medicine, chemical-pharmaceutical industry, homeopathy, gynecology.
SUBSTANCE: invention relates to creature of novel vaginal homeopathic suppository that can be used in treatment of female genitals. Invention proposes nine variants of homeopathic suppository containing sea-buckthorn oil, homeopathic oily extract, oils and homeopathic essences. Proposed suppositories possess the enhanced bioavailability based on addition of homeopathic oily extract in the prescription, improve regenerative function of organs and tissues and enhance effect of basic components that allows their using in homeopathy in treatment of fungal colpitis, vulvovaginitis, endometriosis and papillomas.
EFFECT: improved and valuable medicinal properties of suppository.
9 cl, 20 ex
FIELD: medicine, pharmaceutical industry.
SUBSTANCE: the present innovation deals with developing new medicinal preparations for treating urogenital diseases. The suggested preparation for treating prostatic diseases designed as a suppository that contains the complex of bioregulatory peptides of cattle prostate as a powder with the content of water-soluble peptides being 20%, not less and the foundation, moreover, antimicrobial preparation being the antibiotic or anti-viral preparation, or anti-protozoan preparation, or the mixture of antibiotic and anti-protozoan preparation taken at 1:1 ratio, or the mixture of anti-viral and anti-protozoan preparation taken at 1:1 ratio and the foundation at the following ratio of the components, g/suppository: complex of bioregulatory peptides of cattle prostate 0.05-0.4; antimicrobial preparation 0.7, not more; the foundation - sufficient quantity to obtain the suppository of 2.15-2.35 g weight. The suggested preparation in the form of suppository is of high level of organotropic activity and high level of antimicrobial action that enables to implement etiotropic and pathogenetic therapy of bacterial prostatitis. The innovation provides the action upon an agent and all pathological processes in the affected organ. The innovation enables to treat bacterial prostatic inflammation and that of functionally associated organs.
EFFECT: higher efficiency of therapy.
4 cl, 132 ex, 32 tbl
FIELD: chemical-pharmaceutical industry.
SUBSTANCE: it has been suggested to apply a solid composition for manufacturing a pharmaceutical tablet or a suppository, its melting point being 25°C or higher and it contains an uninterrupted lipid component that contains either one or more than one galactolipids, one or more glyceride ether of fatty acids, possibly one or several out of the following: water and mono-triatomic alcohol at the quantity being up to 15 weight% against the weight of composition, and one or more agent chosen among pharmacologically active agent. The method for manufacturing the composition mentioned includes mixing galactolipids and glyceride ethers of fatty acids followed by dissolving pharmacologically active agents in a liquid phase, cooling up to a solid state and forming a tablet or a filled capsule. Pharmaceutical tablet or suppository are depicted that include uninterrupted lipid phase possibly containing an inert nucleus and, also, food tablets or suppositories of similar composition that include food agents instead of pharmacologically active agent and, possibly, having got one or more submembranes consisting of food excipients. The innovation provides economy and increased comfort in usage.
EFFECT: higher efficiency.
42 cl, 13 ex, 10 tbl
FIELD: microbiology, biotechnology, medicine, in particular production of living vaccines against viral infections.
SUBSTANCE: invention relates to living vaccines for rectal administration against viral infections based on attenuated recombinant Salmonella strains bearing protective viral antigens. Suppository for immunoprophylaxis of viral infections contains (per one 2 g suppository, mass %): cell slurry of attenuated recombinant Salmonella strains transformed with pGEX-2T-TBI, pcDNA-TCI, or pKHBc bearing gene of protective viral antigens, mixed with suppository base in amount of 106-109 living cells 1 %; fatty base 94 %; and emulsifier T2 5 %. As fatty solid cooking oil (94 %); or hydrolyzed cotton oil (94 %); or mixture of cooking oil (60 %), Cocoa fat (24 %), and solid wax (10 %).
EFFECT: agent for inducing of humoral and cell immune response to respective viral antigen.
8 tbl, 11 ex, 3 dwg
FIELD: medicine, gynecology, proctology, pharmacy.
SUBSTANCE: invention relates to medicaments made as vaginal and rectal suppository used in treatment of proctological, non-inflammatory and inflammatory diseases of female pelvis organs, among them complicated with suppurative-inflammatory processes. Invention relates to an agent used in treatment of gynecological and proctological diseases it is made as a suppository and comprises 2-ethyl-6-methyl-3-oxypyridine succinate as an active component and a base chosen from group involving polyethylene oxide-1500, polyethylene oxide-400, cacao butter and hydrogenated fats. Invention provides prolonged release of a curative preparation in mucosa and soft tissues and provides its effect for about 12 h. The procedure is suitable and easy in performance and can be carried out by patients independently under ambulatory conditions.
EFFECT: valuable medicinal and pharmaceutical properties of agent.
3 cl, 2 tbl, 2 ex
FIELD: pharmaceutical industry, in particular agent for prophylaxis and treatment of rheumatoid arthritis and osteoarthritis.
SUBSTANCE: disclosed are suppository having mass of 2-2.5 g containing (g): diclofenac 0.0225-0.0525; glucosamine hydrochloride 0.175-0.525; lecithin 0.057-0.063; and balance: solid fat.
EFFECT: agent for prophylaxis and treatment of arthritis, degenerative joint and backbone diseases with increased anti-inflammatory action and reduced ulcerogenic action.
1 tbl, 3 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to the development of a novel vegetable-base agent that can be used in treatment of inflammatory diseases of small pelvis organs and diseases of rectum. Agent used in prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum comprises long turmeric (Curcuma longa L.) rhizome dried extract standardized by curcumin, anesthetic agent and pharmaceutically acceptable excipients. Agent is made as a suppository and comprises benzocaine as an anesthetic agent and vitepsol and cacao butter as a suppository base. Method for preparing agent used in prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum involves mixing long turmeric dried extract standardized by curcumin with anesthetic agent and a pharmaceutically acceptable excipient. Method for prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum involves using the proposed agent.
EFFECT: improved preparing agent, valuable medicinal properties of agent.
9 cl, 3 ex
FIELD: medicine, homeopathy, pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates, in particular, to suppository possessing immunomodulating effect and comprising coneflower, accessory substances and a base, sea-buckthorn oil, arborvitae (thuja) homeopathic essence, baptisia homeopathic essence, Timalin-1C homeopathic trituratium wherein coneflower is a component of homeopathic essence. Suppository comprises anhydrous lanolin and wax as accessory substances and cacao butter as a base wherein components are taken in the definite ration in grams per one suppository of weight 2 g. Proposed suppository possesses the enhanced immunomodulating effect and allows stimulating processes of regeneration and hemogenesis and improves processes of cellular metabolism.
EFFECT: valuable medicinal properties of suppository.
FIELD: medicine, pharmaceutics.
SUBSTANCE: the present innovation deals with rectal suppositories that contain biphosphonic acids and their pharmacologically acceptable salts applied for preventing and treating diseases caused by affected calcium and magnesium balance in the body. The suggested new suppositories contain 0.1-10 weight% xydiphone and 0.5-10 weight emulsifiers, the rest - the foundation for one suppository of 1.125-2.5 g weight. Rectal xydiphone-containing suppositories could additionally contain medicinal and/or biologically active supplements, for example 0.1-1.0 weight% trisodium salt of phosphonoformic acid as medicinal additive, and, also, biologically active additive chosen out of the group of vitamin B6, B12 or carbon dioxide solution of common camomile, olive oil. The innovation provides the chance to avoid some complications occurred at applying this preparation in known forms and, also, in some cases leads to its increased efficiency.
EFFECT: higher efficiency of application.
4 cl, 4 ex, 1 tbl
SUBSTANCE: method involves modeling acute brain ischemia in animal by means of unilateral extravasal occlusion of common carotid artery. Gamma-interferon is intraperitoneally introduced to mammalian at a dose of 5000 MU/kg of body mass once a day during 3 days before common carotid artery occlusion.
EFFECT: enhanced effectiveness of prophylaxis.
1 dwg, 3 tbl